Fertila – Redefining Global Reproductive Health

Fertila – Redefining Global Reproductive Health
Innovating the global fertility market with unique solutions that reshape the future of health.
The Global Infertility Crisis
17.5%
Couples Affected
Infertility now affects 17.5% of adult couples worldwide, making it one of the fastest-growing health and demographic crises.
50%
Sperm Motility Decline
Over the past 25 years, global sperm motility has dropped by more than half, contributing significantly to fertility challenges.
34%
IVF Success Rate
The primary treatment, IVF, delivers only a 34% success rate per cycle — and results are declining due to deteriorating reproductive cell quality.
$1T
Annual Cost
In the U.S. alone, infertility costs exceed $1 trillion annually in lost productivity, healthcare expenses, and demographic decline.
This is not just a medical challenge — it's an economic one that affects nations worldwide, with similar economic strain mirrored across countries globally.
Our Solution – BioCryo13
Fertila's patented biotechnology, BioCryo13, is engineered to preserve reproductive cells at peak performance — maintaining high viability, stable pH, and optimal energy potential during storage and use.
Improved Cell Quality
By dramatically improving reproductive cell quality, BioCryo13 can raise IVF success rates significantly.
Reduced Treatment Cycles
Better preservation means fewer treatment cycles are needed, reducing both emotional and financial strain on patients.
Lower Costs
More efficient treatments translate to reduced healthcare expenses and greater accessibility to fertility solutions.
Our Vision and Mission
Vision
A world where infertility no longer dictates family, demographic, or economic futures. We aim to address not only fertility outcomes but also the macroeconomic ripple effects caused by population decline.
Mission
To set a new global standard in reproductive health by delivering accessible, ethical, and sustainable technologies that turn scientific innovation into life-changing outcomes for millions of families.
Fertila is committed to making reproductive health solutions accessible across different socioeconomic backgrounds and geographic regions.
Industry Recognition
Fertila's innovative approach to reproductive health has been featured in leading publications and organisations:
Forbes
"Sperm Counts Have Been Falling For Decades … researchers think cell phones could help explain why".
Bloomberg
„Falling fertility rates and aging populations will mean serious challenges“.
European Commission
„In 2023, 3.67 million babies were born in the EU. This is the largest annual decline recorded since 1961.“
The Lancet
„The rapidly diminishing number of children and young people is already reshaping societies”.
Financial Times
“Three‑quarters of the world now live in countries in which the population is actually shrinking".
ESHRE
Shares the latest scientific developments in reproductive medicine.
Research Partnerships
Fertila collaborates with leading academics, also Lithuania Heath Science University, and medical institutions to advance reproductive health research and technology development.
Our research partnerships extend across Europe and beyond, creating a network of expertise that accelerates innovation in reproductive biotechnology.
Through these collaborations, we're able to combine diverse perspectives and specialised knowledge to address the complex challenges of reproductive health. Our partners provide valuable insights, research capabilities, and clinical testing opportunities that help refine our BioCryo13 technology.
Connect With Fertila
Contact Information

Location: Kaunas, Lithuania
Email Us
Follow Us
LinkedIn: Fertila
X: @FertilaHeath
Join us in our mission to redefine reproductive health and create a future where fertility challenges no longer limit personal or societal potential.
BioCryo
Innovation in animal reproduction
UAB “Fertila” is a spin-off company of the Lithuanian University of Health Sciences. Together with a multidisciplinary team of researchers, we are implementing the BioCryo research and development project in collaboration with the Animal Reproduction Laboratory at the University’s Faculty of Veterinary Medicine in Kaunas.
The project is developing BioCryo MT271, a reusable sterile system with microdosing technology designed to help maintain sperm cell viability during storage and transport.
Why is it needed?
Sperm quality during storage and transport matters in animal reproduction. We aim to develop a solution that helps preserve cell viability while reducing the need for single-use materials.
What will we develop and study?
We will optimise the chemical formulation of BioCryo MT271, assess the system’s sterility and biological safety, and develop and test a prototype. We will also analyse and model experimental results using data analysis and artificial intelligence methods.
Later stages will include preparing intellectual property protection documents, testing the solution on partner farms, and developing a commercialisation strategy.
Intended outcome
Our goal is to develop and evaluate BioCryo MT271 in real-world conditions, preparing it for further use in veterinary reproduction.
Project implementer: UAB “Fertila”, a spin-off of the Lithuanian University of Health Sciences
Research collaboration: Animal Reproduction Laboratory, Faculty of Veterinary Medicine, Lithuanian University of Health Sciences, Kaunas
Intended outcome
The project aims to develop and evaluate BioCryo MT271 in real-world conditions, preparing the solution for further use in veterinary reproduction.
Implemented by: UAB “Fertila”
Project: “BioCryo”
The 2022–2030 development programme is managed by the Ministry of Education, Science and Sport of the Republic of Lithuania. Funding sources: EU funds and national co-financing funds.

LT: Projektas bendrai finansuojamas Europos Sąjungos lėšomis

Made with